Fifth Third Bancorp Sells 1,753 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fifth Third Bancorp trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,643 shares of the biopharmaceutical company’s stock after selling 1,753 shares during the period. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $6,157,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after buying an additional 51,162 shares during the last quarter. Principal Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares during the period. Simplify Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $1,334,000. Finally, Daiwa Securities Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after purchasing an additional 2,234 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.7 %

REGN opened at $675.79 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock’s 50 day moving average price is $727.19 and its 200-day moving average price is $936.96. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The stock has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10.

Analyst Upgrades and Downgrades

Several research firms have issued reports on REGN. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.